Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 26;11:8201–8209. doi: 10.2147/OTT.S173008

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Afatinib counteracted CR triggered by NRG1 in LC cells.

Notes: (A) H1299 and (B) HCC78 cells received the supplement of 100 ng/mL NRG1 or 100 ng/mL NGRI and 200 nM afatinib and subsequently underwent incubation with ceritinib for 4 days. MTT assay was used to evaluate the survival. (C) H1299 and (D) HCC78 cells received the supplement of 100 ng/mL of NRG1 and subsequently underwent incubation with 500 nM ceritinib, 200 nM afatinib, or both for 2 days. Cell death was evaluated by the calculation of fragmented as well as condensed nuclei. Data are presented as mean ± SD from three independent experiments. **P<0.01, ceritinib + afatinib vs ceritinib.

Abbreviations: CR, ceritinib resistance; LC, lung cancer.